Partnerships & Collaborations

Our partners

Zai Lab

Karuna and Zai Lab have an exclusive license agreement for the development, manufacturing and commercialization of KarXT in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

Learn more here.


Karuna and PsychoGenics, a phenotypic drug discovery platform company, have a multi-year drug discovery and development agreement to identify potential novel drug candidates for the treatment of severe neuropsychiatric conditions.

Learn more here.

Following the acquisition of Karuna by Bristol Myers Squibb, requests for Patient Advocacy Sponsorships and/or Grants should be submitted through the BMS Corporate Giving portal at